A single-centre, double-blind, parallel, randomised phase I trial investigating the bioequivalence of BOW 015 (infliximab biosimilar) to Remicade in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2016
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Autoimmune disorders
- Focus First in man; Pharmacokinetics
- Sponsors EPIRUS Biopharmaceuticals
- 13 Jun 2015 Pooled safety data from this trial and a phase 3 trial in active rheumatoid arthritis patients presented at the 16th Annual Congress of the European League Against Rheumatism.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 10 Jun 2015 Results presented at the European League Against Rheumatism Annual Congress (EULAR 2015), as reported by EPIRUS media release.